Skip to main content
Equibles

GOLDMAN SACHS GROUP INC

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 886982 NEW YORK, NY
Back to ACAD Full portfolio

Position in ACAD

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$34,676,716
-$7,259,345 QoQ
Shares Held
1,557,804
-0.8% QoQ
Ownership
0.910%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 99.9168701582484.ToString("F0")% Shared 0.ToString("F0")% None 0.08312984175159391.ToString("F0")%

Common Shares in ACAD Over Time

Shares Held

Position Value (USD)

Derivatives in ACAD

reported options exposure · as of Sep 30, 2025
CallValue
$1,916,332
CallShares
89,800
PutValue
$1,916,332
PutShares
89,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $10,294,260,512 across 365 Biotechnology names. ACAD ranks #66 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 2,417,875 $1,079,677,898
2 REGN
Regeneron Pharmaceuticals, Inc.
 1,300,558 $1,004,863,129
3 MRNA
Moderna, Inc.
 6,603,697 $335,467,805
4 ROIV
Roivant Sciences Ltd.
 11,111,591 $307,791,069
5 PRAX
Praxis Precision Medicines, Inc.
 710,734 $228,991,385
6 INCY
Incyte Corp
 2,351,221 $221,296,919
7 RVMD
Revolution Medicines, Inc.
 2,185,500 $212,539,874
8 RYTM
Rhythm Pharmaceuticals, Inc.
 1,965,432 $170,933,620

All Filings in ACAD

Export CSV
44 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $34,676,716 1,557,804
2025-12-31 $41,936,061 1,570,051
2025-09-30 $1,916,332 89,800
2025-09-30 $44,866,282 2,102,450
2025-09-30 $1,916,332 89,800
2025-06-30 $1,936,986 89,800
2025-06-30 $1,936,986 89,800
2025-06-30 $31,675,285 1,468,488
2025-03-31 $1,491,578 89,800
2025-03-31 $1,491,578 89,800
2025-03-31 $36,189,368 2,178,770
2024-12-31 $1,649,665 89,900
2024-12-31 $1,647,830 89,800
2024-12-31 $52,856,513 2,880,464
2024-09-30 $1,382,662 89,900
2024-09-30 $27,051,250 1,758,859
2024-09-30 $1,381,124 89,800
2024-06-30 $1,460,875 89,900
2024-06-30 $1,459,250 89,800
2024-06-30 $21,790,339 1,340,944
2024-03-31 $13,458,961 727,905
2023-12-31 $1,443,391 46,100
2023-12-31 $25,178,562 804,170
2023-09-30 $14,976,144 718,625
2023-06-30 $30,498,504 1,273,424
2023-03-31 $18,438,668 979,738
2022-12-31 $15,770,717 990,623
2022-09-30 $19,311,310 1,180,398
2022-06-30 $14,900,090 1,057,494
2022-03-31 $26,748,010 1,104,377
2021-12-31 $27,586,082 1,181,923
2021-09-30 $13,733,911 826,846
2021-06-30 $13,690,471 561,315
2021-03-31 $26,890,024 1,042,249
2020-12-31 $54,052,870 1,011,090
2020-12-31 $213,840 4,000
2020-09-30 $39,602,763 960,067
2020-09-30 $1,402,500 34,000
2020-09-30 $1,315,875 31,900
2020-06-30 $53,343,464 1,100,546
2020-06-30 $969,400 20,000
2020-06-30 $1,163,280 24,000
2020-03-31 $3,147,625 74,500
2020-03-31 $59,001,153 1,396,477

Report a Problem

Category
Description
Email (optional, for follow-up)